#USA #Duluth #VitaSmart™ #organ preservation #Hope

Introduction

Amid the ongoing advancements in organ transplantation, new data from Bridge to Life™ Ltd. are capturing the attention of the medical community. Recently showcased at the International Liver Transplantation Society (ILTS) Congress 2026 in Geneva, these findings emphasize the substantial potential of the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) system. The main premise is that HOPE not only expands the viability of marginal donor livers but also ensures that mitochondrial function is preserved during the preservation phase, ultimately aiding in real-time assessments of organ viability.

Significance of the Study

The studies presented at the ILTS reinforce the clinical necessity for adopting innovative technologies in organ transplantation. As stated by Don Webber, President and CEO of Bridge to Life, “HOPE is more than just a preservation method; it serves as a recovery tool for organs, helping physicians make better-informed decisions regarding transplant viability.” This insight holds weight, especially considering the escalating numbers of individuals on waiting lists for liver transplants, where conventional methods often lead to suboptimal outcomes.

Expanding Acceptance with HOPE

The findings point toward a marked increase in the acceptance of donor organs within a broader range of criteria. A pivotal study titled “Hypothermic Oxygenated Perfusion (HOPE) Expands Donor Acceptance Criteria With Optimal Outcomes A Multicenter Matched-Cohort Study” involved esteemed institutions across Spain. The researchers observed that adopting HOPE for liver transplants improved outcomes for older donors or those categorized with steatotic conditions, which may have otherwise been discarded. Their results established that HOPE could lead to comparable outcomes to traditional static cold storage while significantly minimizing the risks associated with post-transplant complications.

Recovering Marginal Livers

Another cornerstone of the research was the exploration titled “Recovering the Discarded Livers Using HOPE.” In collaboration with researchers from Vall Hebron Hospital in Barcelona, it was demonstrated that using HOPE significantly improved recovery rates of livers from controlled donors after circulatory death (cDCD). The data indicated a dramatic reduction in previously discarded livers, pointing towards a possibility of reviving organs thought to be unsuitable for transplantation purposes. This could eventually result in a notable increase in viable transplantable organs, benefitting countless patients awaiting lifesaving procedures.

Mitochondrial Function and Logistics

Investigating the preservation of mitochondrial function, a study conducted by the Cleveland Clinic titled “Prolonged HOPE Preserves Mitochondrial Function and Enables Logistical Flexibility in Liver Transplantation” revealed promising outcomes for extended HOPE durations. Their results showed that extending preservation time up to 24 hours maintained mitochondrial integrity, equating its effectiveness with standard short-duration perfusion methods. This extension not only presents clear logistical advantages for coordinated organ transplants but may also support a more versatile framework for organ allocation strategies.

Biomarkers in Organ Viability

Another compelling focus involved exploring Flavinmononucleotide (FMN) levels in donor serum as they relate to organ viability. Findings revealed that FMN could serve as a reliable indicator of mitochondrial damage and predict post-transplant outcomes, thereby enhancing the predictive capabilities concerning graft quality prior to the actual transplantation. The accuracy offered through analyzing FMN could help medical teams make more informed decisions on organ acceptance and tailor preservation methods as needed.

Conclusion

The data revealed during the ILTS 2026 Congress presents a transformative potential for the application of HOPE in organ transplantation, addressing both the logistical challenges and the necessity for improved outcomes. As the field looks towards a future of more precise, data-driven decision-making, Bridge to Life continues to set the standard in organ conservation innovations with their cutting-edge technology. Overall, this research positions HOPE as a pivotal player in the ongoing quest to optimize organ utilization, ultimately saving more lives through transplantation.